Also known as: VLDL cholesterol, VLDL-cholesterol
Polaryx Therapeutics is advancing its SOTERIA Phase 2 basket trial for PLX-200 across four rare pediatric LSDs, with initiation planned for Q4 2026. The company has secured FDA authorization, Fast Track Designation for all four indications, a CRO partner, and $10 million in financing.
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
Orforglipron, an oral GLP-1 receptor agonist, demonstrated greater reductions in HbA1c and body weight compared to oral semaglutide in adults with type 2 diabetes, with more patients achieving strict glycemic targets at one year.
